Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat
<p>Abstract</p> <p>Background</p> <p>Apart from simple steatosis, the non-alcoholic steatohepatitis (NASH) can progress into liver fibrosis and cirrhosis. To date, however, no widely accepted therapeutic modalities have been established against NASH in the clinical prac...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-05-01
|
| Series: | BMC Research Notes |
| Online Access: | http://www.biomedcentral.com/1756-0500/2/70 |
| _version_ | 1828490646901489664 |
|---|---|
| author | Kawaratani Hideto Tsujimoto Tatsuhiro Yamazaki Masaharu Yanase Koji Yoshii Junichi Shirai Yusaku Kaji Kosuke Kitade Mitsuteru Namisaki Tadashi Ikenaka Yasuhide Noguchi Ryuichi Yoshiji Hitoshi Akahane Takemi Aihara Yosuke Fukui Hiroshi |
| author_facet | Kawaratani Hideto Tsujimoto Tatsuhiro Yamazaki Masaharu Yanase Koji Yoshii Junichi Shirai Yusaku Kaji Kosuke Kitade Mitsuteru Namisaki Tadashi Ikenaka Yasuhide Noguchi Ryuichi Yoshiji Hitoshi Akahane Takemi Aihara Yosuke Fukui Hiroshi |
| author_sort | Kawaratani Hideto |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Apart from simple steatosis, the non-alcoholic steatohepatitis (NASH) can progress into liver fibrosis and cirrhosis. To date, however, no widely accepted therapeutic modalities have been established against NASH in the clinical practice. To find out promising new therapeutic agents, it is important to employ an appropriate experimental model of NASH, such as association with insulin resistance.</p> <p>Findings</p> <p>In the current study, we found that losartan, a clinically used angiotensin-II type 1 receptor blocker, significantly attenuated a choline-deficient L-amino acid-defined (CDAA) diet-induced steatohepatitis in obese diabetic- and insulin resistance-associated Otsuka Long-Evans Tokushima Fatty (OLETF) rats. The transforming growth factor-beta, a well-known major fibrogenic cytokine, was also suppressed in a similar magnitude to that of the fibrosis area. Noteworthy was the finding that these inhibitory effects were achieved even at a clinically comparable low dose.</p> <p>Conclusion</p> <p>Since losartan is widely used without serious side effects in the clinical practice, this agent may be an effective new therapeutic strategy against NASH.</p> |
| first_indexed | 2024-12-11T10:47:10Z |
| format | Article |
| id | doaj.art-4dd6c4127f214f7b876370044aad4ebd |
| institution | Directory Open Access Journal |
| issn | 1756-0500 |
| language | English |
| last_indexed | 2024-12-11T10:47:10Z |
| publishDate | 2009-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Research Notes |
| spelling | doaj.art-4dd6c4127f214f7b876370044aad4ebd2022-12-22T01:10:26ZengBMCBMC Research Notes1756-05002009-05-01217010.1186/1756-0500-2-70Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the ratKawaratani HidetoTsujimoto TatsuhiroYamazaki MasaharuYanase KojiYoshii JunichiShirai YusakuKaji KosukeKitade MitsuteruNamisaki TadashiIkenaka YasuhideNoguchi RyuichiYoshiji HitoshiAkahane TakemiAihara YosukeFukui Hiroshi<p>Abstract</p> <p>Background</p> <p>Apart from simple steatosis, the non-alcoholic steatohepatitis (NASH) can progress into liver fibrosis and cirrhosis. To date, however, no widely accepted therapeutic modalities have been established against NASH in the clinical practice. To find out promising new therapeutic agents, it is important to employ an appropriate experimental model of NASH, such as association with insulin resistance.</p> <p>Findings</p> <p>In the current study, we found that losartan, a clinically used angiotensin-II type 1 receptor blocker, significantly attenuated a choline-deficient L-amino acid-defined (CDAA) diet-induced steatohepatitis in obese diabetic- and insulin resistance-associated Otsuka Long-Evans Tokushima Fatty (OLETF) rats. The transforming growth factor-beta, a well-known major fibrogenic cytokine, was also suppressed in a similar magnitude to that of the fibrosis area. Noteworthy was the finding that these inhibitory effects were achieved even at a clinically comparable low dose.</p> <p>Conclusion</p> <p>Since losartan is widely used without serious side effects in the clinical practice, this agent may be an effective new therapeutic strategy against NASH.</p>http://www.biomedcentral.com/1756-0500/2/70 |
| spellingShingle | Kawaratani Hideto Tsujimoto Tatsuhiro Yamazaki Masaharu Yanase Koji Yoshii Junichi Shirai Yusaku Kaji Kosuke Kitade Mitsuteru Namisaki Tadashi Ikenaka Yasuhide Noguchi Ryuichi Yoshiji Hitoshi Akahane Takemi Aihara Yosuke Fukui Hiroshi Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat BMC Research Notes |
| title | Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat |
| title_full | Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat |
| title_fullStr | Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat |
| title_full_unstemmed | Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat |
| title_short | Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat |
| title_sort | losartan an angiotensin ii type 1 receptor blocker attenuates the liver fibrosis development of non alcoholic steatohepatitis in the rat |
| url | http://www.biomedcentral.com/1756-0500/2/70 |
| work_keys_str_mv | AT kawaratanihideto losartananangiotensiniitype1receptorblockerattenuatestheliverfibrosisdevelopmentofnonalcoholicsteatohepatitisintherat AT tsujimototatsuhiro losartananangiotensiniitype1receptorblockerattenuatestheliverfibrosisdevelopmentofnonalcoholicsteatohepatitisintherat AT yamazakimasaharu losartananangiotensiniitype1receptorblockerattenuatestheliverfibrosisdevelopmentofnonalcoholicsteatohepatitisintherat AT yanasekoji losartananangiotensiniitype1receptorblockerattenuatestheliverfibrosisdevelopmentofnonalcoholicsteatohepatitisintherat AT yoshiijunichi losartananangiotensiniitype1receptorblockerattenuatestheliverfibrosisdevelopmentofnonalcoholicsteatohepatitisintherat AT shiraiyusaku losartananangiotensiniitype1receptorblockerattenuatestheliverfibrosisdevelopmentofnonalcoholicsteatohepatitisintherat AT kajikosuke losartananangiotensiniitype1receptorblockerattenuatestheliverfibrosisdevelopmentofnonalcoholicsteatohepatitisintherat AT kitademitsuteru losartananangiotensiniitype1receptorblockerattenuatestheliverfibrosisdevelopmentofnonalcoholicsteatohepatitisintherat AT namisakitadashi losartananangiotensiniitype1receptorblockerattenuatestheliverfibrosisdevelopmentofnonalcoholicsteatohepatitisintherat AT ikenakayasuhide losartananangiotensiniitype1receptorblockerattenuatestheliverfibrosisdevelopmentofnonalcoholicsteatohepatitisintherat AT noguchiryuichi losartananangiotensiniitype1receptorblockerattenuatestheliverfibrosisdevelopmentofnonalcoholicsteatohepatitisintherat AT yoshijihitoshi losartananangiotensiniitype1receptorblockerattenuatestheliverfibrosisdevelopmentofnonalcoholicsteatohepatitisintherat AT akahanetakemi losartananangiotensiniitype1receptorblockerattenuatestheliverfibrosisdevelopmentofnonalcoholicsteatohepatitisintherat AT aiharayosuke losartananangiotensiniitype1receptorblockerattenuatestheliverfibrosisdevelopmentofnonalcoholicsteatohepatitisintherat AT fukuihiroshi losartananangiotensiniitype1receptorblockerattenuatestheliverfibrosisdevelopmentofnonalcoholicsteatohepatitisintherat |